Get access to our best features

Get access to our best features

Published 1 year ago

FDA places clinical hold on Verve Therapeutics gene-editing treatment

Summary by Ground News

Verve Therapeutics says its experimental gene-editing treatment for a common form of heart disease was placed on clinical hold by the FDA. The Cambridge, Mass.-based biotech had submitted a request to the FDA in October to allow participants in the U.S. to receive the CRISPR-based treatment.

0 Articles

0 Articles

All

Left

Center

Right

FDA places clinical hold on Verve Therapeutics gene-editing treatment

The therapy, VERVE-101, uses a form of CRISPR to treat familial hypercholesterolemia, a relatively common form of high cholesterol.

1 year ago·Boston, United States

Read Full Article

GEN - Genetic Engineering and Biotechnology News…

FDA Places Clinical Hold on Verve's Cardio Base Editing Therapy

FDA places clinical hold on Verve Therapeutics' IND application for lead candidate VERVE-101 for Heterozygous Familial Hypercholesterolemia.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center2Last Updated1 year agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

STAT

GEN - Genetic Engineering and Biotechnology News…

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics

Trending Topics

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc.